GigaGen CEO David Johnson to Present at 2017 Antibody Engineering & Therapeutics Meeting

Thursday, December 14, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel

antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2017 Antibody Engineering & Therapeutics Meeting. Dr. Johnson's presentation will take place at 3:30
p.m. PST
on December 15, 2017, at the Manchester Grand Hyatt in San Diego, Calif.

Dr. Johnson's presentation titled, "Discovery of Potent Anti-Tumor TCRs in Recombinant TCR Libraries Generated from Tumor Infiltrating Lymphocytes," will discuss the use of GigaGen's proprietary Surge technology in T cell receptor (TCR) work, which was spun out into a new cellular therapy company, GigaMune, Inc., in summer 2017.

"We are excited by the potential of Surge, our high-throughput single cell droplet microfluidic technology, to help us uncover the role of the T cell repertoire in cancer, infectious diseases and autoimmunity. This unique insight into immune dysregulation is enabled by quickly characterizing T cells within complex immune systems. Our research on T cells thus far has demonstrated the power of Surge to generate a robust portfolio of rare high-potential clinical TCR candidates against novel targets," said Dr. Johnson. "We are particularly encouraged by our latest data on anti-cancer TCRs, which have the potential to form the basis of novel cell therapies."

About GigaGen

GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/gigagen-ceo-david-johnson-to-present-at-2017-antibody-engineering--therapeutics-meeting-300571281.html

SOURCE GigaGen Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store